|
Stock Based Awards and Per Share Information - Additional Information (Detail) (USD $)
|
3 Months Ended | 9 Months Ended | 1 Months Ended | 1 Months Ended | 9 Months Ended | 1 Months Ended | 1 Months Ended | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Sep. 30, 2013
|
Jun. 30, 2013
|
Mar. 31, 2013
|
Sep. 30, 2012
|
Sep. 30, 2013
|
Sep. 30, 2012
|
Dec. 31, 2012
|
Apr. 26, 2013
Sun Dental Warrant
|
Apr. 26, 2013
Sun Dental Warrant
Maximum
|
Apr. 18, 2013
IR Warrant 2
|
Apr. 18, 2013
IR Warrant 2
Maximum
|
Apr. 18, 2013
IR Warrant 2
Minimum
|
Mar. 23, 2013
CMR Warrant
|
Mar. 23, 2013
CMR Warrant
Maximum
|
Sep. 30, 2013
2002 Stock Incentive Plan
|
Sep. 30, 2013
President and COO
|
Jul. 12, 2013
First Tranche
|
Mar. 23, 2013
First Tranche
Minimum
|
Mar. 23, 2013
First Tranche
CMR Warrant
Maximum
|
Mar. 23, 2013
Second Tranche
Minimum
|
Mar. 23, 2013
Second Tranche
CMR Warrant
Maximum
|
Jul. 12, 2013
Valam Warrant
|
Jul. 12, 2013
Fda Clearance
|
Jul. 12, 2013
Second Ent Laser
|
Jul. 12, 2013
Third Ent Laser
|
|
| Stock Based Compensation Activity [Line Items] | |||||||||||||||||||||||||
| Plan expiration date | Apr. 24, 2014 | Apr. 17, 2018 | Mar. 22, 2018 | May 05, 2019 | Jun. 06, 2020 | Jul. 14, 2020 | |||||||||||||||||||
| Common stock authorized for issuance under the 2002 Plan | 7,750,000 | ||||||||||||||||||||||||
| Common stock issued pursuant to options exercised | 2,840,000 | ||||||||||||||||||||||||
| Options outstanding | 4,374,000 | 4,374,000 | 3,860,000 | 4,374,000 | |||||||||||||||||||||
| Options available for future grant | 536,000 | ||||||||||||||||||||||||
| Compensation cost related to stock options | $ 491,000 | $ 357,000 | $ 1,239,000 | $ 1,280,000 | |||||||||||||||||||||
| Net impact of share based compensation expense to earnings per basic share | $ (0.02) | $ (0.01) | $ (0.04) | $ (0.04) | |||||||||||||||||||||
| Net impact of share based compensation expense to earnings per diluted share | $ (0.02) | $ (0.01) | $ (0.04) | $ (0.04) | |||||||||||||||||||||
| Total unrecognized compensation cost | 2,700,000 | 2,700,000 | |||||||||||||||||||||||
| Unrecognized share based compensation cost to be recognized over weighted-average period | 1 year 6 months | ||||||||||||||||||||||||
| Options granted | 1,516,000 | 350,000 | |||||||||||||||||||||||
| Options granted exercise price per share | $ 3.90 | $ 4.00 | |||||||||||||||||||||||
| Options granted to President and COO, vesting period beginning June 6, 2014 | 4 years | ||||||||||||||||||||||||
| Warrants issued to purchase common stock | 500,000 | 60,000 | 100,000 | 50,000 | 50,000 | 165,000 | |||||||||||||||||||
| Warrants price of warrants | 5.90 | 5.10 | 4.50 | 4.50 | 6.00 | ||||||||||||||||||||
| Warrant vesting rate | 1,000 | ||||||||||||||||||||||||
| Stock-based compensation | 1,239,000 | 1,280,000 | 1,000 | ||||||||||||||||||||||
| Minimum required closing price of common stock on the NASDAQ in order to exercise | $ 7.50 | $ 7.50 | $ 10.00 | ||||||||||||||||||||||
| Outstanding stock options and warrants excluded from diluted loss per share | 6,022,000 | 4,504,000 | 6,022,000 | 4,504,000 | |||||||||||||||||||||
| Special stock dividends intended for the year ended 12/31/2013 | 2.00% | ||||||||||||||||||||||||
| Dividends declared, date of record | Aug. 30, 2013 | Jun. 14, 2013 | Mar. 15, 2013 | ||||||||||||||||||||||
| Dividends declared, payable date | Sep. 13, 2013 | Jun. 28, 2013 | Mar. 29, 2013 | ||||||||||||||||||||||
| Special Stock Dividends Declared | 0.50% | 0.50% | 0.50% | ||||||||||||||||||||||
| Vesting of Valam warrant | 30,000 | 55,000 | 40,000 | 40,000 | |||||||||||||||||||||
| ENT laser revenues required during a 12-month period | $ 5,000,000 | $ 10,000,000 | |||||||||||||||||||||||